Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
The new facility will be able to handle four times as many patients as the previous facility.
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
He has published more than 100 research papers in several prestigious national and international journals
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Subscribe To Our Newsletter & Stay Updated
